Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Cerezyme Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Cerezyme (imiglucerase) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Cerezyme enzyme replacement therapy for patients with Gaucher disease. It applies to providers requesting coverage and requires prescribing and administration under the supervision of a physician experienced in treating Gaucher disease.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCerezyme (imiglucerase) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 28, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for long-term enzyme replacement therapy when qualifying Gaucher disease manifestations are documented.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Type 1Primary Gaucher disease indication
    4Qualifying manifestations
    1–2 hoursInfusion duration
    200/400 unitsVial strengths

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1/22/19
    Archived

    Covered Indications and Disease Criteria

    Type 1 Gaucher Disease

    Covered for long-term enzyme replacement therapy when ALL of the following are met:

    ALL of the following

    • Patient has type 1 Gaucher disease.
    • Long-term enzyme replacement therapy is prescribed.
    • At least ONE disease manifestation

      • Anemia.
      • Bone disease.
      • Hepatomegaly or splenomegaly.
      • Thrombocytopenia.

    Off-Label Type 1 or Type 3 Gaucher Disease

    Off-label long-term enzyme replacement therapy may be covered under the Canadian labeling criteria when ALL of the following are met:

    ALL of the following

    • Long-term enzyme replacement therapy is prescribed for Gaucher disease.
    • ONE qualifying disease presentation

      • ALL of the following

        • Patient has type 1 Gaucher disease.
        • At least ONE non-neurological manifestation

          • Anemia.
          • Bone disease.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Obtain prior authorization before initiating or continuing long-term enzyme replacement therapy for patients with type 1 Gaucher disease who meet the qualifying clinical criteria.

    • Therapy must be for type 1 Gaucher disease with at least one qualifying manifestation: anemia, bone disease, hepatomegaly or splenomegaly, or thrombocytopenia.
    Note

    Off-Label Canadian Labeling Criteria

    Authorization may apply under off-label Canadian labeling criteria for long-term enzyme replacement therapy in patients with type 1 Gaucher disease or in patients with type 3 Gaucher disease who have non-neurological manifestations.

    • Qualifying non-neurological manifestations include anemia, bone disease, hepatomegaly or splenomegaly, and thrombocytopenia.

    Therapy and Disease Background

    Cerezyme (imiglucerase) is a recombinant enzyme replacement product and an analogue of glucocerebrosidase. Glucocerebrosidase is deficient in Gaucher disease and normally catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. This policy addresses enzyme replacement therapy for the systemic, non-neurological manifestations of Gaucher disease.

    Key Terms

    Cerezyme (imiglucerase)
    ProductCerezyme (imiglucerase)
    Therapy typeRecombinant enzyme replacement therapy
    Biologic analogueAnalogue of glucocerebrosidase
    Type 1 Gaucher disease
    Disease subtypeType 1 Gaucher disease
    Therapy contextEligible for long-term enzyme replacement therapy
    Manifestation requirementAt least one qualifying manifestation: anemia, bone disease, hepatomegaly or splenomegaly, and thrombocytopenia

    Initial Long-Term Enzyme Replacement Therapy

    Initial Long-Term Enzyme Replacement Therapy

    Initial or requested long-term enzyme replacement therapy must meet all applicable disease, manifestation, and physician-supervision criteria:

    Initial Cerezyme authorization

    • Disease indication: The patient has type 1 Gaucher disease, or type 3 Gaucher disease with non-neurological manifestations under the stated off-label Canadian labeling criteria.
    • Qualifying manifestations: The patient has at least one qualifying manifestation: anemia, bone disease, hepatomegaly or splenomegaly, or thrombocytopenia.At least 1 manifestation
    • Experienced physician supervision: Cerezyme is prescribed by and administered under the supervision of a physician experienced in the treatment of Gaucher disease.

    Administration Supervision

    Note

    Administer Cerezyme under qualified physician supervision

    Cerezyme must be administered in the office under the supervision of a physician experienced in treatment of Gaucher disease.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyCerezyme (imiglucerase) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 28, 2014
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionObtain prior authorization for long-term enzyme replacement therapy when qualifying Gaucher disease manifestations are documented.
    SourceLink
    On This Page
    Covered Indications and Disease CriteriaAuthorization and Documentation RequirementsTherapy and Disease BackgroundKey TermsInitial Long-Term Enzyme Replacement TherapyAdministration Supervision
  1. Hepatomegaly or splenomegaly.
  2. Thrombocytopenia.
  3. ALL of the following

    • Patient has type 3 Gaucher disease.
    • At least ONE non-neurological manifestation

      • Anemia.
      • Bone disease.
      • Hepatomegaly or splenomegaly.
      • Thrombocytopenia.
  4. Documentation Required

    Clinical Indication Documentation

    Document the Gaucher disease type and the qualifying clinical manifestation(s) supporting long-term enzyme replacement therapy.

    • Identify whether the patient has type 1 or type 3 Gaucher disease.
    • Document at least one qualifying manifestation: anemia, bone disease, hepatomegaly or splenomegaly, or thrombocytopenia.
    • For type 3 disease, document that the manifestations are non-neurological.
    Documentation Required

    Qualified Physician Documentation

    Identify the prescribing and supervising physician and document that the physician is experienced in treating Gaucher disease.

    • Cerezyme must be prescribed by and administered under the supervision of a physician experienced in treatment of Gaucher disease.
    • Patients with Gaucher disease and physicians who treat Gaucher disease are encouraged to participate in the International Collaborative Gaucher Group (ICGG) Gaucher Registry; information is available at https://www.registrynxt.com or 1-800-745-4447 (ext. 15500).
    Denial Risk

    Indication Criteria Not Met

    Coverage may be denied when the requested long-term enzyme replacement therapy does not meet the applicable disease-type and manifestation criteria.

    • Type 1 disease without at least one qualifying manifestation—anemia, bone disease, hepatomegaly or splenomegaly, or thrombocytopenia—does not satisfy the authorization criteria.
    • Type 3 disease without documented non-neurological manifestations does not satisfy the off-label Canadian labeling criteria.
    Denial Risk

    Experienced and Supervising Prescriber Required

    Cerezyme must be prescribed by and administered under the supervision of a physician experienced in the treatment of Gaucher disease.

    • Document the supervising physician's Gaucher disease treatment experience.
    • Requests from an inexperienced prescriber or without required physician supervision may be denied.
    Type 3 Gaucher disease
    Disease subtypeType 3 Gaucher disease
    Therapy contextLong-term enzyme replacement therapy under the stated off-label Canadian labeling criteria
    Manifestation requirementNon-neurological manifestations, including anemia, bone disease, hepatomegaly or splenomegaly, and thrombocytopenia